Amgen and Five Prime Therapeutics have announced an agreement under which Amgen will acquire Five Prime Therapeutics for USD 38 per share in cash, representing an equity value of approximately USD 1.9 billion. Five Prime’s lead asset, bemarituzumab, is a Phase 3 ready anti-FGFR2b antibody with Already a subscriber Login…